Navigation Links
TNFerade(TM) Phase III Data Presented at ASCO
Date:6/1/2009

" then "Webcasts & Data" then "Data Presentations."

About PACT

GenVec's PACT trial is a multi-center, randomized, active, and controlled study of 330 patients designed to evaluate the safety and efficacy of TNFerade plus standard of care versus standard of care alone in patients with locally advanced pancreatic cancer. The next interim analysis is expected to occur after two-thirds of the events (or 184 deaths) have occurred in the trial. Results are expected to be announced in early 2010.

About TNFerade(TM)

TNFerade, which has not yet been approved for use, is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF alpha in the tumor. TNFerade has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
4. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
11. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... YORK , May 27, 2015 The ... $416 billion in 2014 and with growth of 8% ... three categories out of pocket: directly on expenditures, co-pays ... drug purchases, and on premiums.  The publisher made its ... Expenditures in the United States ...
(Date:5/28/2015)... , May 28, 2015 A ... - Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, ... $3.6 billion by 2020. The secondary syphilis testing would ... Latin America , Middle ... (LAMEA) market accounted for about 43% revenue share of ...
(Date:5/28/2015)... May 28, 2015  Service Strategies Corp., a ... that Fresenius Kabi, a global healthcare company that ... transfusion and clinical nutrition, has achieved certification under ... Standards for the seventh consecutive year. ... based upon a stringent set of performance criteria ...
Breaking Medicine Technology:Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall of ... Board of Directors members, will be hosting their 34th ... 4-7. For the past 34 years, the Havlicek’s have ... for children by bringing together friends, families, and celebrities ... Havlicek Celebrity Fishing Tournament will be held from June ...
(Date:5/28/2015)... Senior Housing Assistance Group (SHAG) proudly announces a ... Seattle Mariners team that won a record tying 116 ... digital advertising for SHAG to help promote their affordable ... communities slated to open in the next 2 to ... and University Place. , Filming of new commercials starring ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 ... clinic will now be offering Echocardiography Examinations to ... be performed by renowned Qualified Medical Examiner and ... The echocardiography test is a non-invasive and cost-effective ... who are critically ill or have undergone surgery. ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Newton, Mass. (PRWEB) May 28, 2015 ... a $17.5 million round of financing led by ... health solutions company dedicated to transforming health care by ... nation’s largest and most utilized network for exchanging medical ... its growing customer base, increase the breadth of its ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:SHAG Announces New Spokesperson: Lou Piniella 2Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... R788, a novel, oral Syk kinase inhibitor, in ... study showed that R788 (tamatinib fosdium) can improve,platelet ... body attacks and,destroys its own blood platelets. ...
... health assistance in disaster zones is to be presented ... Dr Johan von Schreeb shows that international assistance is ... assessment having been made of the affected population. ... in a number of disaster situations. He examined the ...
... disease, but most remain unaware of it, hampering efforts ... transplant, according to a study funded by the National ... Journal of the American Medical Association. , ... of the U.S. population now have chronic kidney ...
... Corporation,(Amex: CVM ) announced today that its Board ... ensure that all of its stockholders,receive fair and equal ... of CEL-SCI. Geert Kersten, Chief Executive Officer, said ... stage for a cancer indication that has a,multi- billion ...
... the progression of chronic hepatitis C and advanced liver ... to eradicate the disease, a national study in which ... found. , Patients in the trial who were treated ... levels and liver inflammation, but the trial unequivocally demonstrated ...
... children , FRIDAY, Nov. 9 (HealthDay News) -- Certain ... according to studies presented this week at the American ... study found that abatacept, used to treat adults with ... treatment for children and adolescents with severe, treatment-resistant juvenile ...
Cached Medicine News:Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 2Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 4Health News:Humanitarian assistance often lacks needs assessment 2Health News:Chronic kidney disease rises while most people with the condition remain unaware 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: